Impact of breast cancer surgery on angiogenesis circulating biomarkers: A prospective longitudinal study

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Georgiou, Georgios K ^a   Igglezou, Maria ^b   Sainis, Ioannis ^b   Vareli, Katerina ^b   Batsis, Haralampos ^a   Briasoulis, Evangelos ^b   Fatouros, Michalis ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Angiogenesis; Breast cancer; ELISA; PCR arrays; Transcripts

Indexed keywords

BETA3 INTEGRIN; BIOLOGICAL MARKER; CXCL9 CHEMOKINE; EOTAXIN; EPHRIN A3; EPHRIN B2; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 8; LAMININ; LAMININ ALPHA5; METALLOPROTEINASE INHIBITOR 3; NEUROPILIN 1; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SPHINGOSINE KINASE 1; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; BREAST SURGERY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; LONGITUDINAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; UPREGULATION;

ADULT; AGED; ANGIOGENIC PROTEINS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROADENOMA; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-8; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883122193     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-213     Document Type: Article

References (36)

1. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann Oncol 2008, 19:1821-1828. 10.1093/annonc/mdn386, 18550576.
2. Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, Valagussa P, Bonadonna G. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 2005, 16:1449-1457. 10.1093/annonc/mdi280, 15956037.
3. Retsky M, Bonadonna G, Demicheli R, Folkman J, Hrushesky WJ, Valagussa P. Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res 2004, 6:R372-R374. 10.1186/bcr804, 468653, 15217504.
4. Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 2007, 4:699-710. 10.1038/ncponc0999, 18037874.
5. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802. 10.1056/NEJMoa050434, 16120859.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186. 10.1056/NEJM197111182852108, 4938153.
7. Willis L, Alarcon T, Elia G, Jones JL, Wright NA, Tomlinson IP, Graham TA, Page KM. Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res 2010, 70:4310-4317. 10.1158/0008-5472.CAN-09-3144, 20501854.
8. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995, 1:149-153. 10.1038/nm0295-149, 7585012.
9. Pollitt MJ, Hanby AM, Horgan K, Murphy CE, Jones PF, Speirs V. Angiogenesis in breast cancer: how should we measure this? (Review). Oncol Rep 2005, 13:931-936.
10. Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 2007, 4:536-550.
11. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005, 23:1782-1790. 10.1200/JCO.2005.12.017, 15755986.
12. Atkin GK, Chopada A. Tumour angiogenesis: the relevance to surgeons. Ann R Coll Surg Engl 2006, 88:525-529. 10.1308/003588406X117106, 1963738, 17059709.
13. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 2007, 96:1092-1100. 10.1038/sj.bjc.6603678, 2360132, 17353919.
14. Hormbrey E, Han C, Roberts A, McGrouther DA, Harris AL. The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clin Cancer Res 2003, 9:4332-4339.
15. Curigliano G, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, Gandini S, Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A, Goldhirsch A. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Res Treat 2005, 93:35-40. 10.1007/s10549-005-3381-1, 16184456.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31. 10.1038/nm0195-27, 7584949.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
18. Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 2005, 6:209. 10.1186/gb-2005-6-2-209, 551528, 15693956.
19. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Yamashita H, Fukuda M. Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. Breast Cancer 2003, 10:120-128. 10.1007/BF02967636, 12736564.
20. Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003, 9:1144-1155.
21. Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese DJ. EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol 2010, 21:951-960. 10.1016/j.semcdb.2010.08.009, 2991402, 20813200.
22. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007, 5:203-220. 10.1158/1541-7786.MCR-06-0404, 17374728.
23. Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2000, 34:185-194. 10.1016/S1040-8428(00)00062-7, 10838264.
24. Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R, Birner P. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 2006, 139:839-846. 10.1016/j.surg.2005.12.008, 16782443.
25. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011, 437:199-213. 10.1042/BJ20101603, 21711248.
26. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004, 10:7157-7162. 10.1158/1078-0432.CCR-04-0812, 15534087.
27. Green AR, Green VL, White MC, Speirs V. Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 1997, 72:937-941. 10.1002/(SICI)1097-0215(19970917)72:6<937::AID-IJC3>3.0.CO;2-Q, 9378554.
28. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 2000, 349:385-402. 10.1042/0264-6021:3490385, 1221160, 10880336.
29. Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A, Zhao R, Milstien S, Zhou H, Spiegel S, Takabe K. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res 2012, 72:726-735. 10.1158/0008-5472.CAN-11-2167, 3289261, 22298596.
30. Cuvillier O, Ader I, Bouquerel P, Brizuela L, Malavaud B, Mazerolles C, Rischmann P. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 2010, 3:53-65.
31. Takuwa N, Du W, Kaneko E, Okamoto Y, Yoshioka K, Takuwa Y. Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde. Am J Cancer Res 2011, 1:460-481. 3186046, 21984966.
32. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008, 112:41-52. 10.1007/s10549-007-9836-9, 18058224.
33. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. CXC chemokines in angiogenesis. J Leukoc Biol 2000, 68:1-8.
34. Aronica SM, Raiber L, Hanzly M, Kisela C. Antitumor/antiestrogenic effect of the chemokine interferon inducible protein 10 (IP-10) involves suppression of VEGF expression in mammary tissue. J Interferon Cytokine Res 2009, 29:83-92. 10.1089/jir.2008.0034, 19014340.
35. Feldman ED, Weinreich DM, Carroll NM, Burness ML, Feldman AL, Turner E, Xu H, Alexander HR. Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol 2006, 13:125-133. 10.1245/ASO.2006.03.038, 16378159.
36. Duda DG, Sunamura M, Lozonschi L, Yokoyama T, Yatsuoka T, Motoi F, Horii A, Tani K, Asano S, Nakamura Y, Matsuno S. Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficient tumour angiogenesis. Br J Cancer 2002, 86:490-496. 10.1038/sj.bjc.6600067, 2375213, 11875720.